Home
Resources
Publications
Calcipotriene Plus Betamethasone Dipropionate in Aerosol Foam Formulation: Will This Effective Treatment for Mild-To-Moderate Psoriasis Change Clinical Practice?

Calcipotriene Plus Betamethasone Dipropionate in Aerosol Foam Formulation: Will This Effective Treatment for Mild-To-Moderate Psoriasis Change Clinical Practice?

Gian Luigi Giovene, Luca Giacomelli, AIDA (Italian Association of Outpatient Dermatologists) Working Group

G Ital Dermatol Venereol. 2018 Dec;153(6):872-876.

PMID: 30261718

Abstract:

The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in "field-practice" studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP5593204-A	Betamethasone Dipropionate		5593-20-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: